Status: Recruiting
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
Participants needed: 158
Trial details
Phase: Phase 1, Phase 2Age: 18-59Biological sex: MaleType: InterventionalSponsor: Olix Pharmaceuticals, Inc.Updated: Mar 6, 2026Locations: 1
Eligibility criteria
Adult male. [+7]
History or presence of significant pulmonary, hepatic, renal, hematological, gas... [+28]